StockData
CNS Pharmaceuticals, Inc. logo

CNS Pharmaceuticals, Inc. (CNSP) stock

CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$3.56−0.35 (-9.07%)

Close on Nov 20, 2026Market cap $5.20MP/E –Yield –

CNS Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

CNS Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2024 was -$17.12M. For fiscal 2025 it was -$13.83M. The highest annual figure on record is -$716.39K in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$13.83M–
FY2024Dec 31, 2024-$17.12M–
FY2023Dec 31, 2023-$14.14M–
FY2022Dec 31, 2022-$10.56M–
FY2021Dec 31, 2021-$13.54M–
FY2020Dec 31, 2020-$7.34M–
FY2019Dec 31, 2019-$3.57M–
FY2018Dec 31, 2018-$716.39K–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.54M–
Q1 FY2026Mar 31, 2026-$4.65M–
Q2 FY2025Jun 30, 2025-$5.34M–
Q1 FY2025Mar 31, 2025-$3.24M–
Q4 FY2024Dec 31, 2024-$5.48M–
Q4 FY2023Dec 31, 2023-$2.54M–
Q3 FY2023Sep 30, 2023-$3.38M–
Q4 FY2022Dec 31, 2022-$2.31M–
Q3 FY2022Sep 30, 2022-$1.81M–
Q2 FY2022Jun 30, 2022-$3.37M–
Q1 FY2022Mar 31, 2022-$3.08M–
Q4 FY2021Dec 31, 2021-$3.24M–
Q3 FY2021Sep 30, 2021-$2.00M–
Q2 FY2021Jun 30, 2021-$5.00M–
Q1 FY2021Mar 31, 2021-$3.31M–
Q4 FY2020Dec 31, 2020-$1.45M–
Q3 FY2020Sep 30, 2020-$1.27M–
Q2 FY2020Jun 30, 2020-$2.75M–
Q1 FY2020Mar 31, 2020-$1.86M–
Q4 FY2019Dec 31, 2019-$2.49M–
Q3 FY2019Sep 30, 2019-$378.32K–
Q2 FY2019Jun 30, 2019-$625.26K–
Q1 FY2019Mar 31, 2019-$82.69K–
Q4 FY2018Dec 31, 2018-$159.49K–

More CNS Pharmaceuticals figures

See a number that looks wrong?